Research and Markets: US Cancer Pain Market is Projected to Reach $5.3 Billion in 2018, a Compound Annual Growth Rate of 5.5% (2008-2018)
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dc3809/us_cancer_pain_rep) has announced the addition of the "US Cancer Pain Report" report to their offering.
The US market for the drug treatment of cancer pain in 2008 is valued at $3.1 billion, according to US Cancer Pain Report The cancer pain market is dominated by opioid drugs, a trend expected to continue throughout the next decade. The increasing number of cancer pain patients will be the primary driver of market value during the forecast period.
Few of the many drugs in development for pain conditions are seeking regulatory approval for cancer pain. Of these, most are reformulations of fentanyl or other opioids, using novel delivery devices or as combination therapies. Reformulations of existing opioids are unlikely to capture market share unless they can compete economically with older agents that are already available on payer-approved formularies.
Half of the 4.1 million cancer patients in the US experience pain. More than 600,000, among these, experience moderate-to-severe pain. Estimates that the cancer pain market will be valued at $5.3 billion in 2018, based on a patient population of more than 2.5 million cancer pain patients. While most pain is the result of tissue damage caused by the tumor, some cancer pain is due to the effects of chemotherapy, radiation or surgery; moreover, 25% of patients experience more than one type of cancer pain.
Estimates for 2008 and projections to 2018 for SEVEN types of cancer pain: tumor-related, treatment-related, neuropathic, breakthrough pain, malignant bone pain, visceral and soft-tissue. Interviews with oncologists and pain clinicians, as well as data from US Pain Clinic Monitor provide additional perspective on the cancer pain market. US Pain Clinic Monitor is an audit of more than 100 pain clinics that includes prescribing data on cancer pain and 26 other pain indications.
Worldwide, only 25 agents are in active clinical trials for the treatment of cancer pain, but more than 150 agents could have the potential to treat cancer pain. All of these agents are reviewed in this report. Currently, worldwide, 42 drugs with the potential to treat cancer pain have reached Phase III+ in their clinical development. The 15 Phase III+ compounds that are being studied specifically for the treatment of cancer pain include novel delivery approaches for the opioid receptor agonist fentanyl (nine compounds), novel formulations of morphine (two compounds), an NMDA receptor antagonist (intranasal ketamine), a topical combination of ketamine and amitriptyline (NP-1, for chemotherapy-induced neuropathy), an IM sodium channel antagonist (tetrodotoxin), and an oral serotonin receptor agonist that stimulates nerve growth factor release (xaliproden).
Market Value - 2008 and the Future: The US cancer pain market is currently valued at $3.1 billion (2008). Opioids dominate the market ($2.0 billion), followed by medications commonly used to treat inflammatory pain, such as corticosteroids, anesthetics, and NSAIDs (combined, $1.0 billion). Anticonvulsants and antidepressants make up a comparatively small portion of the cancer pain market ($53 million) since they are for treating only those patients with neuropathic pain. During the forecast period the anticonvulsant segment will grow at the same rate as the entire cancer pain market. Growth is this segment will be driven by the continued uptake of Lyrica, which will be patent-protected throughout the forecast period, but tempered by generic gabapentin's ongoing erosion of Neurontin's sales.